Frankfurt - Delayed Quote EUR

Niagen Bioscience, Inc. (OCD1.F)

5.10

+0.10

+(2.00%)

At close: April 8 at 8:08:55 AM GMT+2

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

LOS ANGELES, April 08, 2025--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, reaffirms that the manufacturing of its Niagen® ingredient (patented nicotinamide riboside or NR) and Tru Niagen® and pharmaceutical-grade Niagen® products remain resilient amid the recently enacted global tariffs.

Business Wire yesterday

NAGE
Growth Companies With High Insider Ownership For April 2025

As the U.S. market grapples with the impact of newly announced tariffs, resulting in a sharp decline across major indices like the Dow Jones and Nasdaq, investors are increasingly focused on how these measures might affect economic growth and corporate profits. In such volatile conditions, companies with strong insider ownership often attract attention as they can indicate confidence from those who know the business best; this article highlights three growth companies in the United States...

Simply Wall St. 5 days ago

EXFY

NAGE

BWMN
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Niagen Bioscience fair value estimate is US$7.16 With US$7.52...

Simply Wall St. 13 days ago

NAGE
Why ChromaDex Corp (CDXC) Is Surging In 2025?

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a look at where ChromaDex Corp (NASDAQ:CDXC) stands against other defensive stocks that are surging in 2025. Defensive stocks are surging as investors have been shifting their focus. Growth stocks dominated the […]

Insider Monkey 14 days ago

NAGE
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

LOS ANGELES, March 20, 2025--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent 12,252,506, which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is par

Business Wire 19 days ago

CDXC
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

LOS ANGELES, March 13, 2025--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol "NAGE" effective at stock market open on Wednesday, March 19, 2025.

Business Wire 26 days ago

CDXC
ChromaDex to Present at the 37th Annual Roth Conference

LOS ANGELES, March 11, 2025--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference.

Business Wire 28 days ago

CDXC
Discovering US Market's Hidden Gems with Strong Financials

Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 14% over the past year with earnings projected to grow by 14% annually. In this dynamic environment, identifying stocks with strong financials can be key to uncovering hidden gems that may offer potential opportunities for investors.

Simply Wall St. last month

GSL

GSL-PB

CDXC
ChromaDex Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

A week ago, ChromaDex Corporation ( NASDAQ:CDXC ) came out with a strong set of annual numbers that could potentially...

Simply Wall St. last month

CDXC
Q4 2024 Chromadex Corp Earnings Call

Q4 2024 Chromadex Corp Earnings Call

Thomson Reuters StreetEvents last month

CDXC
ChromaDex Corp (CDXC) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advances

ChromaDex Corp (CDXC) reports a 37% revenue increase and a significant turnaround in net income, while addressing supply chain challenges and competitive pressures.

GuruFocus.com last month

CDXC
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 50% and 7.47%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CDXC
ChromaDex: Q4 Earnings Snapshot

LOS ANGELES (AP) — ChromaDex Inc. CDXC) on Tuesday reported fourth-quarter net income of $7.2 million. On a per-share basis, the Los Angeles-based company said it had profit of 9 cents.

Associated Press Finance last month

CDXC
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

LOS ANGELES, March 04, 2025--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results.

Business Wire last month

CDXC
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

LOS ANGELES, February 25, 2025--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on T

Business Wire last month

CDXC
US Growth Companies With Strong Insider Ownership February 2025

As the U.S. stock market grapples with mixed performances and recent declines in major indices, investors are increasingly focused on the economic outlook and policy impacts from Washington. In this environment, growth companies with strong insider ownership can offer potential stability and alignment of interests between management and shareholders, making them an intriguing focus for those navigating today's volatile market landscape.

Simply Wall St. last month

BWMN

CDXC

ASPI
ChromaDex And 2 Other Undervalued Small Caps In US With Insider Buying

The United States market has remained flat over the past week but has shown a robust 21% increase over the past year, with earnings projected to grow by 14% annually. In this environment, identifying stocks that are potentially undervalued and have insider buying can be a strategic approach for investors seeking opportunities in smaller companies like ChromaDex.

Simply Wall St. last month

PBPB

SNDL

CDXC
Pick These 4 Stocks With Solid Net Profit Margin to Boost Return

Let's take a look at four stocks, GFF, BGC, CHX and CDXC, with impressive net profit margins for a robust portfolio.

Zacks last month

GFF

CDXC
Should Weakness in ChromaDex Corporation's (NASDAQ:CDXC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

With its stock down 18% over the past three months, it is easy to disregard ChromaDex (NASDAQ:CDXC). However, stock...

Simply Wall St. last month

CDXC
US Growth Companies With High Insider Ownership January 2025

As the U.S. equities market navigates a period of mixed trading, with major indices like the S&P 500 reaching record highs amid optimism over corporate earnings and AI advancements, investors are closely monitoring growth companies that demonstrate strong insider ownership. In this environment, stocks with significant insider stakes can be particularly appealing as they often signal management's confidence in the company's future prospects and alignment with shareholder interests.

Simply Wall St. 2 months ago

IMAX

GENI

CDXC

Performance Overview

Return	OCD1.F	S&P 500 (^GSPC)
YTD	-1.92%	-15.28%
1-Year	+34.92%	-4.22%
3-Year	+129.94%	+11.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Niagen Bioscience, Inc. (OCD1.F)

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Growth Companies With High Insider Ownership For April 2025

A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)

Why ChromaDex Corp (CDXC) Is Surging In 2025?

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Discovering US Market's Hidden Gems with Strong Financials

ChromaDex Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Q4 2024 Chromadex Corp Earnings Call

ChromaDex Corp (CDXC) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advances

ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates

ChromaDex: Q4 Earnings Snapshot

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

US Growth Companies With Strong Insider Ownership February 2025

ChromaDex And 2 Other Undervalued Small Caps In US With Insider Buying

Pick These 4 Stocks With Solid Net Profit Margin to Boost Return

Should Weakness in ChromaDex Corporation's (NASDAQ:CDXC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

US Growth Companies With High Insider Ownership January 2025

Performance Overview